How To Ease The Transition From IND-Enabling Studies To GMP Production

How To Ease The Transition From IND-Enabling Studies To GMP Production

Comprehensive pre-work, such as process development and analytical method development, ensures clarity about opportunities and potential pitfalls when going into the GMP batch. This first GMP batch forms the basis for FIH clinical trial material, minimizing manufacturing-related variability and allowing for better comparison of safety and efficacy data.
Slip-ups resulting from a lack of knowledge, experience, or training can lead to delays or even regulator intervention, depending on the severity of the issue. Process development & optimization, raw material sourcing and qualification, quality control & testing, and documentation & batch record-keeping all must be aligned to ensure the GMP batch and, by extension, FIH batch production, is carried out successfully. Moreover, specialized individual and team training, as well as a concerted communication & collaboration campaign, are necessary to create an environment conducive to that success.

By James Schwindeman, Ph.D. LAXAI

Let's Begin The Conversation

    By submitting this form you agree to our Privacy Policy concerning the way LAXAI may use your personal information.

    Address

    Corporate Office

    3rd Floor, Ventureast Plaza, Financial District, Nanakramguda, Hyderabad, 500032, Telangana, India

    GMP Manufacturing Site

    Plot No. 9/A Phase III, IDA Jeedimetla, Hyderabad, Telangana 500055, India

    Discovery Centre

    Building 900, Synergy square I, Genome valley, Turkapally, Shameerpet, Hyderabad, Telangana 500078, India

    US Office

    533 Airport Boulevard Suite 400, Burlingame, CA 94010